New drug combo aims to ease leg pain from clogged arteries

NCT ID NCT07600385

Completed Disease control Sponsor: Korea United Pharm. Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tested whether adding cilostazol to rosuvastatin helps people with peripheral artery disease (PAD) more than rosuvastatin alone. PAD narrows leg arteries, causing pain and trouble walking. The study enrolled 260 adults who took either the combo or a placebo for 24 weeks. Researchers measured changes in walking ability and pain scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cilostazol and rosuvastatin combination
What this could lead to: If successful, this could offer a new treatment option to improve walking ability and reduce leg pain in people with peripheral artery disease.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The combination may not prove significantly better than rosuvastatin alone, and side effects from cilostazol (like headache or diarrhea) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL DISEASE

Contacts and locations

Locations

Yonsei University College of Medicine, Severance Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.